• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics and Variational Al Strengthen Partnership

by Rakovina Therapeutics | Feb 26, 2025 | Uncategorized

DOWNLOAD Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate Al-Powered Collaborations VANCOUVER, British Columbia, Feb. 26, 2025 — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer...

Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

by Rakovina Therapeutics | Feb 6, 2025 | Uncategorized

Vancouver, British Columbia, Feb 6, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program....

Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange

by Rakovina Therapeutics | Jan 31, 2025 | Uncategorized

VANCOUVER, British Columbia, Jan. 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce that its common shares are now listed...

Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference

by Rakovina Therapeutics | Jan 29, 2025 | Uncategorized

January 29, 2025 – Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its participation in the...

Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation

by Rakovina Therapeutics | Jan 22, 2025 | Uncategorized

Vancouver, British Columbia, January 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI...

Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI

by Rakovina Therapeutics | Jan 13, 2025 | Uncategorized

VANCOUVER, British Columbia, Jan. 13, 2025 — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement of a...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media